In today's Wall Street Journal...
When SAC Capital Advisors LP was weighing an investment in Vertex
Pharmaceuticals Inc., VRTX -0.18% the hedge-fund firm contacted a source it
knew would provide nonpublic information without blinking: the federal
An investment manager for an SAC affiliate asked the Food and Drug
Administration last December for any "adverse event reports" for Vertex's
recently approved cystic-fibrosis drug. Under the Freedom of Information
Act, the agency had to hand over the material, which revealed no major
problems. The bill: $72.50, cheaper than the price of two Vertex shares.
Bruce White, CRM, PMP
Virginia Beach, VA
e-mail: [log in to unmask]
Sometimes the questions are complicated
and the answers are simple.
List archives at http://lists.ufl.edu/archives/recmgmt-l.html
Contact [log in to unmask] for assistance
To unsubscribe from this list, click the below link. If not already present, place UNSUBSCRIBE RECMGMT-L or UNSUB RECMGMT-L in the body of the message.
mailto:[log in to unmask]